An Ad2/Ad5-hybrid lacking the E1B-55K gene, which acts in part through binding and inactivating p53, dl1520 was originally proposed to replicate selectively in tumour cells lacking p53 function and was originally developed by Onyx Pharmaceuticals (USA)34. This evidence concerns the gene TP53 and neoplasm.